Form 4: Artivion Director Daniel J. Bevevino Receives Restricted Stock Grant

Artivion, Inc. Director Daniel J. Bevevino was granted 6,325 shares of common stock as a Restricted Stock Award, vesting in May 2026.

Summary

• Daniel J. Bevevino, a Director of Artivion, Inc. (AORT), acquired 6,325 shares of common stock on May 22, 2025.
• The acquisition was a Restricted Stock Award (RSA) grant, with a transaction price of $0 per share.
• Following this transaction, Mr. Bevevino beneficially owns a total of 150,061 shares of Artivion common stock.
• The RSA grant is scheduled to vest on May 22, 2026, in accordance with the terms of the company's Equity and Cash Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a standard, expected compensation event that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The Restricted Stock Award aligns the director's interests with those of the shareholders, incentivizing long-term performance.
• The grant is part of a pre-existing Equity and Cash Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The issuance of new shares, even as a grant, can result in minor dilution for existing shareholders, though the amount is relatively small in this instance.

Future Outlook

The document indicates a future vesting event for the granted shares on May 22, 2026, which is part of the company's long-term incentive structure.

Industry Context

This Form 4 filing reflects a standard practice in the medical device industry, where equity-based compensation, such as Restricted Stock Awards, is commonly used to incentivize and retain key directors and executives, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Awards (RSAs) for director compensation is a common practice across various industries, including medical devices, aligning with typical corporate governance standards for executive and board incentives.
• The grant size of 6,325 shares to a director is within a reasonable range for a company of Artivion's likely market capitalization, comparable to similar grants observed at peer companies in the medical technology sector, such as Edwards Lifesciences (EW) or Boston Scientific (BSX), though specific grant sizes vary based on company size and individual roles.

Stakeholder Impact

• Shareholders: The grant represents a minor dilution but aims to align the director's long-term interests with shareholder value creation.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The 6,325 Restricted Stock Award shares granted to Daniel J. Bevevino are scheduled to vest on May 22, 2026.

Key Dates

Keywords

Artivion, AORT, SEC Form 4, Restricted Stock Award, RSA Grant, Director Compensation, Equity Incentive Plan, Insider Transaction, Stock Ownership, Corporate Governance